Table 5:
HT1080 Cell
| Compound | 50 mM glutamate | 2.5 μM erastin | 1 μM RSL3 |
|---|---|---|---|
| No treatment | 10.1 ± 4.7% | 11.7 ± 2.5% | 14.2 ± 2.8% |
| Ferrostatin (10 μM) | 59.4 ± 1.3%**** | 75.7 ± 5.9%**** | 90.8 ± 4.8%**** |
| Liproxstatin (1 μM) | 56.9 ± 3.5%**** | 72.8 ± 1.9%**** | 88.6 ± 3.7%**** |
| Deferiprone (100 μM) | 71.0 ± 4.1%**** | 73.0 ± 5.0%**** | 83.4 ± 5.1%**** |
| MitoQ (1 μM) | 90.2 ± 7.1%**** | 89.8 ± 3.3%**** | 64.3 ± 2.3%**** |
| Clorgyline (100 μM) | 66.3 ± 12.8%**** | 73.3 ± 3.2%**** | 72.0 ± 4.5%**** |
| 968 (10 μM) | 67.4 ± 8.9%**** | 69.8 ± 7.0%**** | 81.7 ± 6.7%**** |
| GSK2795039 (10 μM) | 64.8 ± 7.4%**** | 69.6 ± 7.0%**** | 67.1 ± 4.5%**** |
| GKT137831 (10 μM) | 63.7 ± 6.6%**** | 70.7 ± 7.8%**** | 76.9 ± 9.6%**** |
| PD146176 (5 μM) | 66.9 ± 7.8%**** | 72.2 ± 8.1%**** | 49.7 ± 4.6%**** |
| Troglitazone (1 μM) | 65.5 ± 5.6%**** | 72.0 ± 1.0%**** | 86.2 ± 5.1%**** |
| Idebenone (1 μM) | 78.8 ± 3.6%**** | 74.9 ± 2.5%**** | 77.5 ± 2.5%**** |
| CoCl2 (100 μM) | 61.4 ± 5.4%**** | 53.8 ± 2.9%**** | 56.1 ± 6.2%**** |
| LY83583 (1 μM) | 64.2 ± 3.8%**** | 68.6 ± 2.2%**** | 86.0 ± 6.7%**** |
| Apomorphine (5 μM) | 86.9 ± 1.0%**** | 54.4 ± 4.9%**** | 93.6 ± 7.1%**** |
| BI-6C9 (10 μM) | 60.6 ± 1.2%**** | 69.6 ± 1.5%**** | 77.9 ± 6.8%**** |
| Bafilomycin (100 nM) | 25.5 ± 4.0% | 18.0 ± 6.6% | 4.0 ± 2.7% |
| Scriptaid (10 μM) | 16.9 ± 9.5% | 15.6 ± 3.7% | 12.0 ± 1.0% |
| Nullscript (10 μM) | 3.8 ± 1.7% | 0.2 ± 0.3% | 5.0 ± 3.0% |
| Flt3 inhibitor (1 μM) | 71.7 ± 4.2%**** | 70.1 ± 2.5%**** | 90.9 ± 8.7%**** |
The oxytosis/ferroptosis inhibitors that were effective against glutamate, erastin and RSL3 in the HT22 cells as shown in Table 1 were tested for their ability to protect human HT1080 cells against glutamate, erastin and RSL3 toxicity at doses that induce 85%-95% cell death. Initially, the same inhibitor concentrations that were effective in the HT22 cells were tested. If no protection was seen, then a range of concentrations was tested. The most effective concentrations are reported here. The values presented are the average of a minimum of three independent experiments with all treatments done in triplicate.
****
p<0.0001 versus glutamate, erastin or RSL3 alone.